Stock GABA GABATHER AB
Add to a list
To use this feature you must be a member
Log inSign up

Gabather AB Stock

Equities

GABA

SE0010869552

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:48 2024-05-28 am EDT 		5-day change 1st Jan Change
1.575 SEK +2.61% Intraday chart for Gabather AB -5.69% +11.70%
Apr. 10 Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002 CI
Mar. 18 Gabather Submits Two US Patent Applications for GT-002 Use in Psychiatric Disorders MT

Financials

Sales 2021 - Sales 2022 - Capitalization 61.73M 654M
Net income 2021 -17M -180M Net income 2022 -8M -84.71M EV / Sales 2021 -
Net cash position 2021 14.85M 157M Net cash position 2022 6.27M 66.41M EV / Sales 2022 -
P/E ratio 2021
-3.57 x
P/E ratio 2022
-7.21 x
Employees 3
Yield 2021 *
-
Yield 2022
-
Free-Float 99.97%
More Fundamentals * Assessed data

Chart Gabather AB

Dynamic Chart

Latest news about Gabather AB

Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002 CI
Gabather Submits Two US Patent Applications for GT-002 Use in Psychiatric Disorders MT
Gabather AB Files Two New Patent Applications to Secure Novel Findings on the Effects of GT-002 for the Treatment of Neuropsychiatric Disorders CI
Gabather AB Reports Initial Positive Results from the EEG/fMRI Target Engagement Study CI
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Gabather AB Approaches a Significant Milestone in the Clinical Development of GT-002 CI
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers CI
Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Gabather AB Receives Notice of Approval from the Japanese Patent Office for National Phase Application CI
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Gabather Secures Notice Of Allowance For US Patent Claims Covering Neuropsychiatric Drug Synthesis MT
More news

Press releases Gabather AB

Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002 AQ
Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders AQ
Gabather reports initial positive results from the EEG/fMRI target engagement study AQ
Gabather AB receives initial EEG data analysis from the GT-002 target engagement study AQ
Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD) AQ
More press releases

Quotes and Performance

1 day+2.61%
1 week-5.69%
Current month-21.05%
1 month-14.40%
3 months+67.91%
6 months+21.62%
Current year+11.70%
More quotes

Highs and lows

1 week
1.47
Extreme 1.465
1.68
1 month
1.47
Extreme 1.465
2.50
Current year
0.79
Extreme 0.792
2.98
1 year
0.79
Extreme 0.792
4.69
3 years
0.79
Extreme 0.792
8.40
5 years
0.79
Extreme 0.792
16.00
10 years
0.79
Extreme 0.792
92.40
More quotes

Managers and Directors - Gabather AB

Managers TitleAgeSince
Michael Robin Witt CEO
 Chief Executive Officer - 14-08-31
Kristofer Svensson DFI
 Director of Finance/CFO - -
Christine Natasha Ryan COO
 Chief Operating Officer - -
Members of the board TitleAgeSince
Michael Robin Witt CEO
 Chief Executive Officer - 14-08-31
Bert Roland Kari Junno BRD
 Director/Board Member 58 20-12-31
Anders Lönnberg CHM
 Chairman - 20-12-31
More insiders

Quotes

Date Price Change Volume
24-05-28 1.575 +2.61% 18,683
24-05-27 1.535 -0.97% 27,347
24-05-24 1.55 -3.13% 10,272
24-05-23 1.6 -1.84% 6,302
24-05-22 1.63 -2.40% 26,671

Delayed Quote Nasdaq Stockholm, May 28, 2024 at 11:29 am EDT

More quotes

Company Profile

Gabather AB is a Sweden-based company engaged pharmaceutical industry. The Company develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The Company mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimer’s disease.
Sector
Biotechnology & Medical Research
Calendar
2024-05-29 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GABATHER AB Stock Gabather AB
+11.70% 2.82M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.83% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.80% 105B
BIONTECH SE Stock BioNTech SE
-10.84% 22.71B
ARGENX SE Stock argenx SE
-1.69% 21.83B
GENMAB A/S Stock Genmab A/S
-10.23% 18.18B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.92% 16.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.11% 16.01B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.62% 14.14B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+17.53% 10.71B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GABA Stock